Jo Ellen Klaustermeier

TL;DR: HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines, according to this largest assessment of HPV genotypes to date.

TL;DR: Molecular evidence of carcinogenicity for types currently classified as probably/possibly carcinogenic HR‐HPV types is provided, although this evidence is not sufficient for inclusion of these HPV types into population‐wide primary and secondary prevention programmes.

TL;DR: The data confirms the association of cervical NET with HPV and p16INK4a overexpression and indicates that current HPV vaccines could largely prevent these aggressive tumors.

TL;DR: To describe human papillomavirus distribution in invasive cervical carcinoma from Mali and Senegal and to compare type‐specific relative contribution among sub‐Saharan African countries is compared.

TL;DR: The study provides baseline information for further evaluation on the impact of recently introduced HPV vaccines in Italy and describes the prevalence of HPV and the HPV type-specific distribution in ICC cases identified in Rome, Italy.